Baidu
map

内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

梅斯作为媒体参加第九届全国糖尿病足及慢性创面修复论坛

2016-10-08 MedSci MedSci原创

糖尿病足创面修复
关注













版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1631984, encodeId=271f163198434, content=<a href='/topic/show?id=b88a321e6b2' target=_blank style='color:#2F92EE;'>#创面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32176, encryptionId=b88a321e6b2, topicName=创面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fda21837820, createdName=qindq, createdTime=Sun Aug 20 13:42:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276877, encodeId=38d612e687738, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511291, encodeId=3a77151129188, content=<a href='/topic/show?id=6ea8321e7b1' target=_blank style='color:#2F92EE;'>#创面修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32177, encryptionId=6ea8321e7b1, topicName=创面修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62f510322384, createdName=ms9651749636653578, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142315, encodeId=1a6614231586, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:35:01 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142314, encodeId=82af14231445, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:34:52 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142004, encodeId=db6f142004ae, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Oct 08 11:05:58 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2017-08-20 qindq

    #创面#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1631984, encodeId=271f163198434, content=<a href='/topic/show?id=b88a321e6b2' target=_blank style='color:#2F92EE;'>#创面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32176, encryptionId=b88a321e6b2, topicName=创面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fda21837820, createdName=qindq, createdTime=Sun Aug 20 13:42:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276877, encodeId=38d612e687738, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511291, encodeId=3a77151129188, content=<a href='/topic/show?id=6ea8321e7b1' target=_blank style='color:#2F92EE;'>#创面修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32177, encryptionId=6ea8321e7b1, topicName=创面修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62f510322384, createdName=ms9651749636653578, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142315, encodeId=1a6614231586, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:35:01 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142314, encodeId=82af14231445, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:34:52 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142004, encodeId=db6f142004ae, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Oct 08 11:05:58 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-10 一闲

    #梅斯#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1631984, encodeId=271f163198434, content=<a href='/topic/show?id=b88a321e6b2' target=_blank style='color:#2F92EE;'>#创面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32176, encryptionId=b88a321e6b2, topicName=创面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fda21837820, createdName=qindq, createdTime=Sun Aug 20 13:42:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276877, encodeId=38d612e687738, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511291, encodeId=3a77151129188, content=<a href='/topic/show?id=6ea8321e7b1' target=_blank style='color:#2F92EE;'>#创面修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32177, encryptionId=6ea8321e7b1, topicName=创面修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62f510322384, createdName=ms9651749636653578, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142315, encodeId=1a6614231586, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:35:01 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142314, encodeId=82af14231445, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:34:52 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142004, encodeId=db6f142004ae, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Oct 08 11:05:58 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-10 ms9651749636653578

    #创面修复#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1631984, encodeId=271f163198434, content=<a href='/topic/show?id=b88a321e6b2' target=_blank style='color:#2F92EE;'>#创面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32176, encryptionId=b88a321e6b2, topicName=创面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fda21837820, createdName=qindq, createdTime=Sun Aug 20 13:42:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276877, encodeId=38d612e687738, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511291, encodeId=3a77151129188, content=<a href='/topic/show?id=6ea8321e7b1' target=_blank style='color:#2F92EE;'>#创面修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32177, encryptionId=6ea8321e7b1, topicName=创面修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62f510322384, createdName=ms9651749636653578, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142315, encodeId=1a6614231586, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:35:01 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142314, encodeId=82af14231445, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:34:52 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142004, encodeId=db6f142004ae, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Oct 08 11:05:58 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-09 知难而进

    继续关注！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1631984, encodeId=271f163198434, content=<a href='/topic/show?id=b88a321e6b2' target=_blank style='color:#2F92EE;'>#创面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32176, encryptionId=b88a321e6b2, topicName=创面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fda21837820, createdName=qindq, createdTime=Sun Aug 20 13:42:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276877, encodeId=38d612e687738, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511291, encodeId=3a77151129188, content=<a href='/topic/show?id=6ea8321e7b1' target=_blank style='color:#2F92EE;'>#创面修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32177, encryptionId=6ea8321e7b1, topicName=创面修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62f510322384, createdName=ms9651749636653578, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142315, encodeId=1a6614231586, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:35:01 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142314, encodeId=82af14231445, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:34:52 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142004, encodeId=db6f142004ae, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Oct 08 11:05:58 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-09 知难而进

    谢谢分享！

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1631984, encodeId=271f163198434, content=<a href='/topic/show?id=b88a321e6b2' target=_blank style='color:#2F92EE;'>#创面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32176, encryptionId=b88a321e6b2, topicName=创面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fda21837820, createdName=qindq, createdTime=Sun Aug 20 13:42:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276877, encodeId=38d612e687738, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511291, encodeId=3a77151129188, content=<a href='/topic/show?id=6ea8321e7b1' target=_blank style='color:#2F92EE;'>#创面修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32177, encryptionId=6ea8321e7b1, topicName=创面修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62f510322384, createdName=ms9651749636653578, createdTime=Mon Oct 10 01:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142315, encodeId=1a6614231586, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:35:01 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142314, encodeId=82af14231445, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:34:52 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142004, encodeId=db6f142004ae, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Oct 08 11:05:58 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-08 忠诚向上

    好好学习

    0

相关资讯

CDS 2015：MedSci专访许樟荣教授：糖尿病足预防及分级管理

2015年12月9日—12日，由中华医学会、中华医学会糖尿病学分会（CDS）主办，江苏省医学会承办的“中华医学会糖尿病学分会第十九次全国学术会议（CDS 2015）”在苏州国际博览中心举行。 梅斯医学（MedSci）有幸采访了中国人民解放军第 306 医院全军糖尿病诊治中心主任许樟荣教授。 MedSci：许教授，您好！感谢您接受MedSci的采访。您在今年第七届国际糖尿病足大会上作为中国唯

糖尿病足创面清创：“去”和“留”的抉择

糖尿病足创面有时因感染较重、组织破坏广泛以及伴有肌腱及骨组织的外露，单纯换药难以使创面在短期内愈合。因此，及时有效的清创对促进糖尿病足创面愈合十分必要，手术清创过程中对坏死组织的识别清除，以及对健康组织的保留和保护是决定清创效果的关键因素。

难治性糖尿病足溃疡或许不再“难治”

难治性糖尿病足溃疡是指糖尿病足溃疡经过标准治疗2～6周后无好转甚至溃疡恶化者。难治性糖尿病足溃疡或肌腱、骨关节暴露的足溃疡给临床医生的治疗带来巨大挑战，既增加住院时间和住院费用，又增加截肢和死亡风险，大大降低了糖尿病患者生活质量。

李炳辉——糖尿病足处理的临床路径

在2015年国际腔内血管学大会，来自华中科技大学同济医学院附属梨园医院的李炳辉主任为我们介绍了糖尿病足处理的临床路径。 糖尿病足坏疽是糖尿病最常见且较严重的并发症之一，有截肢及威胁患者生命的可能。作为临床医生，需明确认识危险因素，及时有效的对患者进行治疗；需多学科团队合作，降低下肢截肢的风险；若发生截肢，应明确截肢平面，尽量保障肢体功能。 初步病情评估：

“糖尿病足”可增加患者认知功能障碍的风险！

糖尿病足增加民众认知障碍风险

盘点：糖尿病足治疗及指南一览

糖尿病足溃疡是指糖尿病患者由于合并神经病变及各种不同程度的末梢血管病变而导致足部感染、溃疡形成和（或）深部组织破坏。其临床特点为早期肢端麻木、疼痛、发凉和（或）有间歇性跛行、静息痛，或痛觉不明显，足部温暖，但有麻木感，皮肤干燥、干裂，进而出现皮肤溃疡，继而出现水疱、血泡、糜烂、溃疡、肌腱变性坏死、坏疽等表现。这里梅斯小编整理了关于糖尿病足治疗的重要研究进展及重大指南与各位分享.【1】2015

Baidu
map
Baidu
map
Baidu
map